Pharnext SA
PAR:ALPHA
Pharnext SA
Total Current Liabilities
Pharnext SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharnext SA
PAR:ALPHA
|
Total Current Liabilities
€10.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Current Liabilities
€150.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Liabilities
€41.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
14%
|
|
|
Inventiva SA
PAR:IVA
|
Total Current Liabilities
€58.5m
|
CAGR 3-Years
35%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Current Liabilities
$49.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
20%
|
|
|
Abivax SA
PAR:ABVX
|
Total Current Liabilities
€112m
|
CAGR 3-Years
49%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Pharnext SA
Glance View
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Issy-Les-Moulineaux, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
See Also
What is Pharnext SA's Total Current Liabilities?
Total Current Liabilities
10.9m
EUR
Based on the financial report for Jun 30, 2023, Pharnext SA's Total Current Liabilities amounts to 10.9m EUR.
What is Pharnext SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
3%
Over the last year, the Total Current Liabilities growth was -55%. The average annual Total Current Liabilities growth rates for Pharnext SA have been 5% over the past three years , 3% over the past five years .
